Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.78 |
| ▸ | HTR2A | P28223 | 6/20 | 0.78 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861539 | 0.89 | MCHR1 (0.98) | MCHR1CHRM1HTR2ACACNA1GATM | |
| SCHEMBL3879260 | 0.89 | MCHR1 (0.98) | MCHR1CHRM1HTR2ACACNA1GATM | |
| SCHEMBL4009683 | 0.88 | MCHR1 (1.00) | MCHR1CHRM1HTR2ACACNA1GATM | |
| SCHEMBL3867112 | 0.87 | MCHR1 (0.74) | MCHR1CHRM1HTR2ACACNA1GATM | |
| SCHEMBL3858644 | 0.83 | MCHR1 (0.79) | MCHR1CHRM1HTR2ACACNA1GNPC1 | |
| SCHEMBL3866378 | 0.81 | MCHR1 (0.76) | MCHR1CHRM1HTR2ACACNA1GATM | |
| SCHEMBL3865129 | 0.80 | MCHR1 (0.74) | MCHR1CHRM1HTR2ACACNA1GATM | |
| SCHEMBL3859312 | 0.80 | CHRM1 (0.79) | MCHR1CHRM1HTR2ARAB9A | |
| SCHEMBL3859310 | 0.80 | CHRM1 (0.79) | MCHR1CHRM1HTR2ARAB9A | |
| SCHEMBL3866815 | 0.80 | MCHR1 (0.72) | MCHR1CHRM1HTR2ACACNA1GATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1708698-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005063239-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | MCHR1 1/4885CHRM1 103/4885HTR2A 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.